Please login to the form below

Not currently logged in

RPSGB provides logo to make online drug purchases safer

The Royal Pharmaceutical Society of Great Britain launches a new internet logo scheme to help people validate authentic websites for their online medicine purchases
In order to make the purchase of drugs on the web safer, the Royal Pharmaceutical Society of Great Britain (RPSGB) has launched a new internet logo scheme to help people validate authentic websites for their online purchases. The logo will appear on registered websites including a hyperlink to the society's website where visitors can verify the registration details of both the pharmacy and pharmacist. According to the RPSBG, approximately 2.3 million people in the UK buy prescription medicines online, but up to one third of these medicines are fake and present a danger to peopleís health. Research also reveals that many UK citizens are unaware of online regulations for medical sites, with 1 in 20 believing that foreign websites are fully regulated. An educational web video available to watch free of charge and free of copyright restrictions at the following website:

10th January 2008


Featured jobs

Subscribe to our email news alerts


Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...